SNX5 Inhibitors
The chemical class termed SNX5 inhibitors constitutes a varied assembly of compounds characterized by their capacity to interact with and modulate the activity or interactions of SNX5 (Sorting Nexin 5), a prominent member of the sorting nexin protein family. SNX5 is recognized for its involvement in orchestrating intricate cellular processes encompassing endocytic trafficking, membrane sorting, and intracellular signaling. Inhibitors within this class are meticulously engineered to interface with SNX5, with the aim of impacting its functional contribution to these cellular pathways. These inhibitors deploy diverse strategies to achieve this modulation, encompassing interventions that interfere with SNX5's molecular interactions or biochemical activity.
Mechanistically, SNX5 inhibitors adopt multifaceted approaches. They might disrupt protein-protein interactions involving SNX5, thereby influencing its participation in cellular processes. Alternatively, they could target specific domains within SNX5, such as its BAR (Bin/Amphiphysin/Rvs) domain, to exert influence on its membrane curvature sensing and binding capabilities. Furthermore, some inhibitors might intersect with downstream cellular components or pathways that SNX5 associates with, amplifying their potential to influence SNX5-mediated functions. Structurally, SNX5 inhibitors boast a landscape spanning diverse chemical archetypes. The spectrum encompasses small organic molecules identified through high-throughput screening endeavors, compounds that modulate phosphorylation dynamics, and those that might have effects on SNX5's stability. Additionally, inhibitors might leverage insights from the intricate interplay between SNX5 and related proteins, potentially targeting pathways involved in vesicle trafficking or endosome dynamics.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Direct inhibitor targeting SNX5. ML-7 is a myosin light chain kinase (MLCK) inhibitor, affecting the phosphorylation of myosin light chains. This disruption influences actin cytoskeleton dynamics, impacting SNX5's involvement in endosomal trafficking and membrane remodeling processes. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Direct inhibitor acting on SNX5 by blocking the GTPase activity of dynamin. This disruption interferes with endocytic processes, affecting the recruitment and function of SNX5 in endosomal trafficking and sorting events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Indirect inhibitor impacting SNX5 through the PI3K/AKT pathway. LY294002 inhibits PI3K, leading to decreased AKT activation. This alteration influences SNX5-mediated endosomal sorting and membrane trafficking processes through the modulation of phosphoinositide levels. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Indirect inhibitor affecting SNX5 through N-WASP inhibition. Modulating actin polymerization dynamics, Wiskostatin alters SNX5 recruitment and function in cellular processes involving actin cytoskeleton rearrangement and endocytic trafficking. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Indirect inhibitor influencing SNX5 through lysosomal function. Chloroquine disrupts lysosomal acidification, impacting endosomal maturation processes and altering SNX5's role in endosomal sorting and trafficking events. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Indirect inhibitor affecting SNX5 through actin dynamics. Disrupting actin filament polymerization, Latrunculin B alters SNX5 recruitment and function in processes involving actin-myosin interactions and endocytic trafficking. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Indirect inhibitor modulating SNX5 through Rho-associated protein kinase (ROCK) inhibition. Alters actin cytoskeleton dynamics, affecting SNX5 recruitment and function in processes such as endosomal trafficking and sorting. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Direct inhibitor targeting clathrin-mediated endocytosis. Pitstop 2 inhibits clathrin assembly, impacting the recruitment of SNX5 to clathrin-coated pits during endocytic processes. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
Direct inhibitor affecting SNX5 by disrupting the Arp2/3 complex. Inhibits actin nucleation, leading to changes in actin dynamics that influence the recruitment and function of SNX5 during cellular processes involving actin cytoskeleton organization and endosomal trafficking. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Indirect inhibitor influencing SNX5 through actin dynamics. Stabilizes F-actin, leading to alterations in SNX5 recruitment during endosomal trafficking and membrane remodeling processes. | ||||||